chartexchange

Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Business Wire | Nov 10, 2026 4:05 PM EST

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahe

Read original article